Wearable biofeedback system improves balance in Parkinson’s patients

Researchers at the University of Houston in the Department of Health and Human Performance are hoping to improve quality of life for Parkinson’s patients with a wearable belt connected to a smartphone application to help users regain balance.

The Smarter Balance System (SBS) is a personalized wearable, smartphone-connected biofeedback rehabilitation system that guides patients though balance rehabilitation exercises. Using vibrating actuators, the system utilizes “touch guidance” to guide and map a patient’s movements in real-time that can be reviewed on a smartphone.

"The smartphone application records and creates a custom motion for their body tilt based on their individual limits of stability. The touch guidance from the vibrating actuators is almost acting as if a physical therapist is guiding them," said Alberto Fung, University of Houston graduate student and part of the Sensori-Motor Augmentation & Rehabilitation Technology (SMART) Research Group.

In a six week, at-home study, researchers noted users experienced noticeable improvements.

"Our overarching goal is to improve their quality of life by improving postural stability, reducing the number of falls and increasing their confidence in daily activities," said Beom-Chan Lee, assistant professor and principle investigator of the study, which is assessing the impacts of long-term rehabilitative training on patients using the SBS system developed by Lee's team. "It's important to develop a system that is easy to use and readily available in the home environment. Most of the time, patients have to rehab at a clinic but there might be limited access. We're not trying to replace traditional therapy but there is a shortage of physical therapists."

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.